stockrow
Saturday 7 November 2026
Export APVO’s income statement to Excel — free account
Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million.
- EPS
- +96.5%
- Free cash flow
- +23.1%
Quarter to June 2026, against a year earlier
1.24
0.03
−2.36%
Follow APVO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.75 | 3.57 | 3.05 | 1.89 | |
Current Ratio |
4.03 | 3.82 | 3.36 | 2.08 | |
Net Debt/EBITDA |
2.79 | 3.65 | 2.14 | 1.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.89 | 1.17 | 0.86 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(29.71) | (5.28) | (7.51) | (4.56) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(29.71) | (5.28) | (7.51) | (4.56) | |
Cash per Share |
93.56 | 21.79 | 13.69 | 8.19 | |
Shareholders Equity per Share |
77.26 | 17.52 | 10.95 | 5.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
77.26 | 17.52 | 10.95 | 5.05 | |
Free Cash Flow |
(6.69) | (5.24) | (7.96) | (5.45) | |
Working Capital |
17.04 | 17.03 | 11.22 | 5.61 | |
Net Current Asset Value |
13.05 | 13.27 | 7.69 | 2.32 | |
| Other line items | |||||
Average Payables |
2.88 | 1.06 | 2.34 | 2.03 | |
Average Assets |
21.07 | 21.39 | 14.12 | 15.07 | |
Average Common Equity |
10.91 | 11.07 | 5.07 | 6.28 |
Columns are period end dates · fundamentals updated 26 Oct 2026